Abstract:Over the past decades, therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) and their main active metabolites has shown benefits in improving treatment efficacy and safety. Therefore, a sensitive, simple and economical ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of six oral tyrosine kinase inhibitors (TKIs) and two active metabolites, including imatinib (IMA), N-desmethyl imatinib (NDIMA), sunitinib (SUNI), N-desethyl sunitinib (NDSUNI), regorafenib (REGO), nilotinib (NILO), dasatinib (DASA) and osimertinib (OSI) in human plasma/serum for therapeutic drug monitoring. The plasma/serum samples were deproteinated with acetonitrile after spiking with two deuterated internal standards (ISs, [2H8]-imatinib and [2H10]-sunitinib) and separated on a 40 °C ACQUITY UPLC® BEH C18 column (1.7 µm, 2.1 mm × 50 mm). The mobile phase was composed of acetonitrile (solution A) and water-formic acid-ammonium acetate (1 M) (994:1:5, v/v/v, solution B). Gradient elution was applied at a flow rate of 0.4 mL/min. Detection was carried out using a Triple Quad 5500 tandem mass spectrometer coupled with an electrospray ionization (ESI) source in positive mode. The method was validated over the calibration curve (CV) range of 2-400 ng/mL for NDSUNI and DASA, 2.5-500 ng/mL for SUNI, 10-2000 ng/mL NDIMA and OSI, 20-4000 ng/mL for NILO, 30-6000 ng/mL for REGO and 50-10000 ng/mL for IMA using linear regression and 1/x2 weighting. No difference was observed in the matrix effect (ME) among blank human plasma, hemolytic plasma, lipemic plasma, plasma spiked with ten commonly used drugs by cancer patients, or serum samples in general. The standard curve fitted by two standard curves of serum and plasma showed good linearity, and the precision and accuracy results of QC samples in both plasma and serum were acceptable and the concentration was comparable. To provide a clinical reference for the operation, the stability of the whole process from sample collection to drug detection was verified. SUNI and NDSUNI showed obvious photoisomerization under light exposure. Therefore, strict light protection was applied for all sample collection and handling steps of SUNI and NDSUNI. Compared with heparin anticoagulant tubes, the stability of the eight compounds in both whole blood and plasma was better in K3-EDTA and sodium citrate anticoagulant tubes. Given that all the analytes were stable in plasma at 4 °C for 48 h and in whole blood at room temperature for 48 h but OSI and REGO were unstable in whole blood and plasma at room temperature, samples should be centrifuged as soon as possible to be preserved as plasma at 4 °C when OSI or REGO is detected. In conclusion, this validated method can provide support for clinical practice, such as therapeutic drug monitoring (TDM) and pharmacokinetic studies of these six TKIs and two active metabolites.

Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high‐performance liquid chromatography–diode array detection combined with a second‐order calibration method

Fast Quantitative Analysis of Four Tyrosine Kinase Inhibitors in Different Human Plasma Samples Using Three-Way Calibration-Assisted Liquid Chromatography with Diode Array Detection.

A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of thirty-nine tyrosine kinase inhibitors in human plasma

Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS

Comparison of Three Chemometric Methods for Processing HPLC-DAD Data with Time Shifts: Simultaneous Determination of Ten Molecular Targeted Anti-Tumor Drugs in Different Biological Samples

Simultaneous Determination of Tyrosine and Levodopa in Human Plasma Using Enzyme-Induced Excitation-Emission-Kinetic Third-Order Calibration Method

Development and Clinical Application of a Liquid Chromatography-Tandem Mass Spectrometry-Based Assay to Quantify Eight Tyrosine Kinase Inhibitors in Human Plasma.

Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies

Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies

Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS

Second-order Calibration Applied to Quantification of Two Active Components of Schisandra Chinensis in Complex Matrix.

Chemometric Resolution of Coeluting Peaks of Eleven Antihypertensives from Multiple Classes in High Performance Liquid Chromatography: A Comprehensive Research in Human Serum, Health Product and Chinese Patent Medicine Samples

A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines

Chemometrics-enhanced High Performance Liquid Chromatography-Diode Array Detection Strategy for Simultaneous Determination of Eight Co-Eluted Compounds in Ten Kinds of Chinese Teas Using Second-Order Calibration Method Based on Alternating Trilinear Decomposition Algorithm

Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC–MS/MS for therapeutic drug monitoring

Simultaneous and Rapid Determination of 12 Tyrosine Kinase Inhibitors by LC-MS/MS in Human Plasma: Application to Therapeutic Drug Monitoring in Patients with Non-Small Cell Lung Cancer

MonoTip C18 pipette tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry enables rapid and automated therapeutic drug monitoring of tyrosine kinase inhibitors

High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma

Method Development and Validation for Simultaneous Determination of Six Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using UPLC–MS/MS for Therapeutic Drug Monitoring

Simultaneous and Interference-Free Determination of Eleven Non-Steroidal Anti-Inflammatory Drugs Illegally Added into Chinese Patent Drugs Using Chemometrics-Assisted HPLC-DAD Strategy

Solving Signal Instability to Maintain the Second-Order Advantage in the Resolution and Determination of Multi-Analytes in Complex Systems by Modeling Liquid Chromatography–mass Spectrometry Data Using Alternating Trilinear Decomposition Method Assisted with Piecewise Direct Standardization